[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Piechocki MP, Dibbley SK, Lonardo F, Yoo GH: Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer; 2008 Apr 15;122(8):1722-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed a decrease in the number and size of lobules and lobular nodules in treated mice with a reduction in the overall disease burden per gland.
  • The development of acinic cell carcinoma in the parotid glands of these animals was also reduced coincident with decreased stromal involvement during progression.
  • At the same time MAPK activity and cytokine production in splenocytes and lymph nodes was increased in gefitinib-treated animals coincident with an increase in lymph node size.
  • These studies demonstrate the critical role of HER2 signal transduction in the onset and progression of HER2/neu-dependent breast cancer and suggest a role for specific inhibitors to prevent the outgrowth of early hyperplastic disease.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Administration, Oral. Animals. Carcinoma, Acinar Cell / drug therapy. Carcinoma, Acinar Cell / prevention & control. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / prevention & control. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Mice. Mice, Inbred BALB C. Mice, Transgenic. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Rats. Signal Transduction / drug effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076070.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


2. Cheuk DK, Shek TW, Chan GC, Lau YL, Ha SY, Chiang AK: Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Mar;50(3):636-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
  • Salivary gland tumors account for about 6% of the second cancers.
  • The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland.
  • We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor.
  • Careful monitoring for recurrence or a third malignancy is needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Acinar Cell / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Parotid Neoplasms / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. 6-Mercaptopurine / adverse effects. Adenoma, Sweat Gland / etiology. Adenoma, Sweat Gland / surgery. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child, Preschool. Combined Modality Therapy / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Prednisolone / administration & dosage. Prednisolone / adverse effects. Recurrence. Remission Induction. Survivors. Sweat Gland Neoplasms / etiology. Sweat Gland Neoplasms / surgery. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16865683.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; UKALL X protocol
  • [Number-of-references] 17
  •  go-up   go-down


Advertisement
3. Christensen NR, Charabi S, Johansen LS, Rygaard J, Balle VH, Tos M, Thomsen J: Effect of photodynamic therapy on a heterotransplanted human parotid tumor. Auris Nasus Larynx; 2000 Jul;27(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of photodynamic therapy on a heterotransplanted human parotid tumor.
  • To evaluate the effect of photodynamic therapy on human parotid tumors we used tumor specimens obtained from parotid surgery on a consecutive group of patients.
  • The original human tumors were pleomorphic adenoma (four), adenolymphoma (one), acinic cell carcinoma (one), sarcoma (one) and low-grade adenocarcinoma (one).
  • The current study demonstrates that the nude mice implantation model is excellent to investigate growth in both malignant and benign parotid tumors, and to test new therapeutic modalities.
  • Photodynamic therapy seems to have a possible role in the future management of the malignant lesions of the parotid gland, in cases where radical surgery for some reason is not achievable.
  • [MeSH-major] Neoplasm Transplantation. Parotid Neoplasms / drug therapy. Photochemotherapy. Transplantation, Heterologous
  • [MeSH-minor] Animals. Female. Humans. Leg / innervation. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Necrosis. Neovascularization, Pathologic / pathology. Nervous System / pathology. Postoperative Period

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10808112.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down






Advertisement